Navigating Life Sciences M&A Deals Beyond COVID-19

Despite the various impacts of the COVID-19 pandemic, the life sciences industry has remained among the most active sectors for M&A activity. Check out this practice note, by Reb Wheeler of Mayer Brown LLP, focusing on issues common in life sciences M&A transactions and discussing some of the factors contributing to robust deal activity in the industry in recent years and what may be in store as industry participants continue to navigate a world transformed by COVID-19.       

READ NOW »

Related Content

• Life Sciences Due Diligence Considerations in M&A Checklist
  Familiarize yourself with key M&A due diligence concerns in this highly regulated industry.

• Life Sciences in International Jurisdictions
  Access international guides addressing essential aspects of life sciences law and policy.

• FDA Drug Regulatory Activity Tracker
  Stay current on the latest Food and Drug Administration regulatory guidance on medical drugs with this tracker from Practical Guidance’s Life Sciences practice area.

Practical Guidance Updates 
Featuring the latest updates from your Practical Guidance account.  

• The Practical Guidance Journal Spring 2022 Edition includes market trends on De-SPAC transactions.
• Check out the new Practical Guidance Author Center! Learn about the 1500+ leading attorney authors contributing to our 20 practice areas, and find out how you can Become a Practical Guidance Author.
• Document alerts allow you to stay current on legal developments that affect your practice. Find out how to set up your document alerts.

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+